Robot-assisted versus open radical cystectomy: no clear signs of immediate benefit

Many readers of this blog have probably heard or read the reports like this one on the CBS Evening News or this one on the Reuters web site that there were no significant short-term (perioperative) differences in outcome between robot-assisted radical cystectomy (complete removal of the bladder) and the older open surgical procedure. … READ MORE …

NICE approves coverage for enzalutamide by NHS

The National Institute for Health and Care Excellence (NICE) has issued final approval for coverage of treatment with enzalutamide (Xtandi) for men with metastatic, castrated-resistant prostate cancer (mCRPC) who have already received prior treatment with docetaxel-based chemotherapy. … READ MORE …

The potential promise of BLZ-100 or “tumor paint”

There has been a lot of media interest in the past couple of weeks in a new technology that may be very helpful in enhancing the visibility of cancerous tissues and the ability to differentiate visually between cancerous and healthy tissue. … READ MORE …

Quality of life after standard therapies for localized prostate cancer

Assessment of patient quality of life (QoL) after standard forms of treatment for localized prostate cancer is difficult for many reasons — not least because there is no real agreement among members of the research community about the best ways to measure QoL or patient satisfaction after treatment. … READ MORE …

ART or SRT in high-risk patients post-surgery?

As many of our regular readers will know, there is no clear answer to the question whether, among men at elevated risk of progressive disease after first-line surgery, it is better to have adjuvant radiation therapy (ART) within a few months of surgery or to wait until salvage radiation therapy (SRT) is clearly advisable. … READ MORE …

No 15-year survival benefit associated with primary ADT in older men

In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …

Physicians’ attitudes and the management of low-risk prostate cancer in older American men

According to newly published data in JAMA Internal Medicine and discussed on the Reuters web site today, “physician characteristics may play a larger role than disease characteristics when it comes to how patients with low-risk prostate cancer are initially treated.” This won’t come as a big surprise to most experienced prostate cancer advocates. … READ MORE …

If you’re already depressed, you may need help to make good decisions

In a rather less that surprising finding, a new paper in the Journal of Clinical Oncology reports that men with existing depressive disorders at the time of diagnosis with prostate cancer “are less likely to undergo definitive treatment and experience worse overall survival.” … READ MORE …

Antioxidants and cancer: do they, could they really work?

For much of the past 30 years or so there has been a great deal of effort to try to prove that antioxidants — and most specifically dietary antioxidants like some vitamins — can be used to either prevent the onset of certain cancers or to prevent the progression of early-stage cancers after a diagnosis. … READ MORE …

Another kinase inhibitor shows only “modest” activity in men with mCRPC

A relatively small Phase II trial, carried out in France and Germany, has suggested that a new kinase inhibitor called nintedanib has only “modest” activity in the treatment of post-chemotherapy, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Low insurance, high risk (for prostate cancer mortality among African Americans)

A recently published paper in the journal Urologic Oncology has confirmed that (regrettably but unsurprisingly), here in the USA, African-American men with high-risk prostate cancer are significantly less likely than white males to be given definitive treatment with curative intent. … READ MORE …

Urologists recommend AS more often than rad/oncs (but probably not enough)

A new article on the Medscape web site, based on an article by Kim et al. in the journal Medical Care, deals with urologists’ and radiation oncologists’ recommendations for active surveillance (AS) as an appropriate form of treatment for low-risk prostate cancer in the USA today. … READ MORE …

Lancet comments on PBRT in treatment of prostate cancer

On June 5 we had noted that, the day before, the American Society for Radiation Oncology (ASTRO) released its model policy on the use of proton beam radiation therapy (PBRT) and related reimbursement issues. … READ MORE …

Suicide gene therapy for prostate cancer: some VERY early data

Data from a small, distinctly esoteric, Phase II clinical trial of a form of prostate cancer suicide gene therapy along with radiation therapy have suggested that such treatment may be able to stop the development of some early stage forms of prostate cancer (but such data need to be interpreted with great care). … READ MORE …

Don’t docetaxel and drive!

Every so often one learns something quite unexpected that one probably should have been aware of previously. This is salutary … but it is also a good thing! … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,115 other followers